Francis Joseph Giles

Professor M.B.B.Ch.BAO.,MD,FRCPI,FRCPath

Contact Details

Director
Clinical Research Facility Galway
Geata an Eolais
University Road
Galway

T: 091495970
F: 091585852
E: frank.giles@nuigalway.ie
 
researcher

Biography

Peer Reviewed Journals

  Year Publication
(1988) 'Alpha-interferon therapy for essential thrombocythaemia'
Giles FJ, Singer CR, Gray AG, Yong KL, Brozovic M, Davies SC, Grant IR, Hoffbrand AV, Machin SJ, Mehta AB (1988) 'Alpha-interferon therapy for essential thrombocythaemia'. Lancet, 2 (8602):70-72 [Details]
(1990) 'Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response'
de Mel WC, Hoffbrand AV, Giles FJ, Goldstone AH, Mehta AB, Ganeshaguru K (1990) 'Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response'. British journal of haematology, 74 (4):452-456 [Details]
(1991) 'alpha-Interferon in hematological malignancies'
Giles FJ, Ozer H (1991) 'alpha-Interferon in hematological malignancies'. HNO, 2 (6):847-850 [Details]
(1991) 'Recombinant alpha-interferons, thyroid irradiation and thyroid disease'
Giles FJ, Worman CP, Jewell AP, Goldstone AH (1991) 'Recombinant alpha-interferons, thyroid irradiation and thyroid disease'. Acta haematologica, 85 (3):160-163 [Details]
(1991) 'Maintenance therapy in the myeloproliferative disorders: the current options'
Giles FJ (1991) 'Maintenance therapy in the myeloproliferative disorders: the current options'. British journal of haematology, 79 Suppl 1 :92-95 [Details]
(1992) 'Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells'
Jewell AP, Worman CP, Giles FJ, Goldstone AH, Lydyard PM (1992) 'Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells'. Leuk Lymphoma, 7 (5-6):473-480 [DOI] [Details]
(1992) 'Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cells'
Jewell AP, Yong KL, Worman CP, Giles FJ, Goldstone AH, Lydyard PM (1992) 'Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cells'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 6 (5):400-404 [Details]
(1993) 'Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia'
McSweeney EN, Giles FJ, Worman CP, Jewel AP, Tsakona CP, Hoffbrand AV, Mehta AB, Newland AC, Cawley JC, Galvani D (1993) 'Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia'. British journal of haematology, 85 (1):77-83 [Details]
(1994) 'Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo'
Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH (1994) 'Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo'. British journal of haematology, 88 (2):268-274 [Details]
(1994) 'Secondary myelodysplastic syndromes and leukemias'
Giles FJ, Koeffler HP (1994) 'Secondary myelodysplastic syndromes and leukemias'. Current opinion in hematology, 1 (4):256-260 [Details]
(1994) 'Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL'
Jewell AP, Yong KL, Worman CP, Tsakona CP, Giles FJ, Goldstone AH (1994) 'Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL'. British journal of haematology, 86 (2):441-443 [Details]
(1995) 'Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation'
Jewell AP, Lydyard PM, Worman CP, Giles FJ, Goldstone AH (1995) 'Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation'. Leuk Lymphoma, 18 (1-2):159-162 [DOI] [Details]
(1996) 'Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia'
Jewell AP, Giles FJ (1996) 'Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia'. Leuk Lymphoma, 21 (3-4):347-349 [DOI] [Details]
(1997) 'Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy'
Jewell AP, Worman CP, Giles FJ, Goldstone AH (1997) 'Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy'. Leuk Lymphoma, 24 (3-4):327-333 [DOI] [Details]
(1998) 'Translocation (3;21;8)(q21;q22;q22) in a patient with acute myeloid leukemia. A case report and review of prognostic indicators'
Giles FJ, Kanemaki TJ, Schreck RR, Qasabian L, Fuerst MP, Lim SW (1998) 'Translocation (3;21;8)(q21;q22;q22) in a patient with acute myeloid leukemia. A case report and review of prognostic indicators'. Gene, 104 (1):66-69 [Details]
(1999) 'Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance'
Giles FJ, Kantarjian HM, Cortes J, Thomas DA, Talpaz M, Manshouri T, Albitar M (1999) 'Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance'. Cancer, 86 (5):805-813 [Details]
(1999) 'Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy'
Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ (1999) 'Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy'. Cancer, 86 (7):1216-1230 [Details]
(2000) 'A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study '
Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, Azim HA, Bapsy PP, Buyukkececi F, Chaimongkol B, Chen PM, Cheong SK, Ferhanoglu B, Hamza R, Khalid HM, Intragumtornchai T, Kim SW, Kim SY, Koc H, Kumar L, Kumar R, Lei KI, Lekhakula A, Muthalib A, Patel M, Poovalingam VP, Prayoonwiwat W, Rana F, Reksodiputro AH, Ruff P, Sagar TG, Schwarer AP, Song HS, Suh CW, Suharti C, Supindiman I, Tee GY, Thamprasit T, Villalon AH, Wickham NR, Wong JE, Yalcin A, Jootar S (2000) 'A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study '. Leuk Lymphoma, 40 (1-2):95-103 [DOI] [Details]
(2001) 'Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts'
Estey EH, Thall PF, Cortes JE, Giles FJ, O'Brien S, Pierce SA, Wang X, Kantarjian HM, Beran M (2001) 'Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts'. Blood, 98 (13):3575-3583 [Details]
(2001) 'High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens'
Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH (2001) 'High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens'. Cancer, 92 (8):1999-2015 [Details]
(2001) 'Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome'
Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ (2001) 'Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome'. Leuk Lymphoma, 42 (3):329-337 [DOI] [Details]
(2001) 'Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia'
Giles FJ, Cortes JE, Baker SD, Thomas DA, O'Brien S, Smith TL, Beran M, Bivins C, Jolivet J, Kantarjian HM (2001) 'Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia'. Journal Of Clinical Oncology, 19 (3):762-771 [Details]
(2002) 'Central nervous system relapse in adults with acute lymphoblastic leukemia'
Surapaneni UR, Cortes JE, Thomas D, O'Brien S, Giles FJ, Koller C, Faderl S, Kantarjian H (2002) 'Central nervous system relapse in adults with acute lymphoblastic leukemia'. Cancer, 94 (3):773-779 [Details]
(2002) 'Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia'
Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, Thomas DA, Andreeff M, Bivins C, Jolivet J, Kantarjian HM (2002) 'Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia'. Journal Of Clinical Oncology, 20 (3):656-664 [Details]
(2002) 'Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders'
Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ (2002) 'Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders'. Leuk Lymphoma, 43 (4):767-772 [DOI] [Details]
(2002) 'Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase'
Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M (2002) 'Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase'. Blood, 99 (10):3547-3553 [Details]
(2002) 'Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia'
Giles FJ, Cortes JE, Thomas DA, Garcia-Manero G, Faderl S, Jeha S, De Jager RL, Kantarjian HM (2002) 'Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia'. Cancer Research, 8 (7):2134-2141 [Details]
(2002) 'The emerging role of angiogenesis inhibitors in hematologic malignancies'
Giles FJ (2002) 'The emerging role of angiogenesis inhibitors in hematologic malignancies'. Oncology, 16 (5 Suppl 4):23-29 [Details]
(2002) 'CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia'
Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM (2002) 'CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia'. Leukemia research, 26 (7):643-649 [Details]
(2003) 'Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia'
Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O'Brien S, Kantarjian HM, Giles FJ (2003) 'Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia'. Cancer Chemother Pharmacol, 52 (6):449-452 [DOI] [Details]
(2003) 'Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia'
Tsimberidou A, Cortes J, Thomas D, Garcia-Manero G, Verstovsek S, Faderl S, Albitar M, Kantarjian H, Estey E, Giles FJ (2003) 'Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia'. Leukemia research, 27 (10):893-897 [Details]
(2003) 'Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders'
Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM, Albitar M, Kantarjian HM, Giles FJ (2003) 'Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders'. Cancer Chemother Pharmacol, 52 (3):229-234 [DOI] [Details]
(2003) 'Rituximab in relapsed or refractory hairy cell leukemia'
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM (2003) 'Rituximab in relapsed or refractory hairy cell leukemia'. Blood, 102 (12):3906-3911 [DOI] [Details]
(2003) 'Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease'
Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O'Brien SM, Keating MJ, Kantarjian HM, Armitage JO, Albitar M (2003) 'Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease'. British journal of haematology, 123 (5):850-857 [Details]
(2003) 'Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies'
Zhang Y, Wang Z, Liu H, Giles FJ, Lim SH (2003) 'Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies'. Journal of immunotherapy (Hagerstown, Md. : 1997), 26 (6):461-467 [Details]
(2003) 'Monoclonal antibodies in the treatment of lymphoid leukemia'
O'Brien S, Giles FJ (2003) 'Monoclonal antibodies in the treatment of lymphoid leukemia'. Drugs, 39 (7):541-550 [Details]
(2003) 'Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia'
Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V (2003) 'Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia'. Leukemia research, 27 (12):1077-1083 [Details]
(2003) 'Phase II study of alemtuzumab in chronic lymphoproliferative disorders'
Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ (2003) 'Phase II study of alemtuzumab in chronic lymphoproliferative disorders'. Cancer, 98 (4):773-778 [DOI] [Details]
(2003) 'Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies'
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ (2003) 'Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies'. Blood, 101 (9):3413-3415 [DOI] [Details]
(2003) 'Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia'
Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M (2003) 'Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia'. British journal of haematology, 120 (3):452-456 [Details]
(2003) 'A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression'
Giles FJ, Bekele BN, O'Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M (2003) 'A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression'. British journal of haematology, 121 (4):578-585 [Details]
(2003) 'OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL'
Tomkinson B, Bendele R, Giles FJ, Brown E, Gray A, Hart K, LeRay JD, Meyer D, Pelanne M, Emerson DL (2003) 'OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL'. Leukemia research, 27 (11):1039-1050 [Details]
(2004) 'Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies'
Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) 'Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies'. Blood, 103 (5):1635-1640 [DOI] [Details]
(2004) 'Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay'
Jilani I, Keating M, Giles FJ, O'Brien S, Kantarjian HM, Albitar M (2004) 'Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay'. Leukemia research, 28 (12):1255-1262 [DOI] [Details]
(2004) 'Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma'
Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H (2004) 'Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma'. Blood, 104 (6):1624-1630 [DOI] [Details]
(2004) 'The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies'
Wang Z, Zhang Y, Mandal A, Zhang J, Giles FJ, Herr JC, Lim SH (2004) 'The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies'. Cancer Research, 10 (19):6544-6550 [DOI] [Details]
(2004) 'A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia'
Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M (2004) 'A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia'. Leukemia research, 28 (4):353-357 [DOI] [Details]
(2004) 'An update on the management of chronic lymphocytic leukaemia'
Yee KW, O'Brien SM, Giles FJ (2004) 'An update on the management of chronic lymphocytic leukaemia'. Expert opinion on pharmacotherapy, 5 (7):1535-1554 [DOI] [Details]
(2005) 'Richter's syndrome: biology and therapy'
Yee KW, O'Brien SM, Giles FJ (2005) 'Richter's syndrome: biology and therapy'. Cancer, 11 (3):161-174 [Details]
(2005) 'Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies'
Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ (2005) 'Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies'. Cancer Research, 11 (18):6615-6624 [DOI] [Details]
(2005) 'Management of intracranial fungal infections in patients with haematological malignancies'
Mattiuzzi G, Giles FJ (2005) 'Management of intracranial fungal infections in patients with haematological malignancies'. British journal of haematology, 131 (3):287-300 [DOI] [Details]
(2005) 'Clinical experience with decitabine in North American patients with myelodysplastic syndrome'
Yee KW, Jabbour E, Kantarjian HM, Giles FJ (2005) 'Clinical experience with decitabine in North American patients with myelodysplastic syndrome'. Annals of hematology, 84 Suppl 1 :18-24 [DOI] [Details]
(2006) 'Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies'
Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'brien S, Verstovsek S, Faderl S, Zhou X, Raad II, Bekele BN, Leitz GJ, Lopez-Roman I, Estey EH (2006) 'Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies'. Antimicrobial Agents And Chemotherapy, 50 (1):143-147 [DOI] [Details]
(2006) 'The role of gemtuzumab ozogamicin in acute leukaemia therapy'
Tsimberidou AM, Giles FJ, Estey E, O'Brien S, Keating MJ, Kantarjian HM (2006) 'The role of gemtuzumab ozogamicin in acute leukaemia therapy'. British journal of haematology, 132 (4):398-409 [DOI] [Details]
(2006) 'New agents in myelodysplastic syndromes'
Jabbour E, Giles FJ (2006) 'New agents in myelodysplastic syndromes'. Current hematologic malignancy reports, 1 (1):25-33 [DOI] [Details]
(2006) 'Thalidomide therapy for myelofibrosis with myeloid metaplasia'
Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O'Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM (2006) 'Thalidomide therapy for myelofibrosis with myeloid metaplasia'. Cancer, 106 (9):1974-1984 [DOI] [Details]
(2006) 'Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia'
Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O'Brien S, Giles FJ, Albitar M (2006) 'Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia'. British journal of haematology, 133 (6):690-692 [DOI] [Details]
(2006) 'Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation'
Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ (2006) 'Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation'. Journal Of Clinical Oncology, 24 (15):2343-2351 [DOI] [Details]
(2006) 'Novel approaches in the treatment of systemic mastocytosis'
Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S (2006) 'Novel approaches in the treatment of systemic mastocytosis'. Cancer, 107 (7):1429-1439 [DOI] [Details]
(2006) 'Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies'
Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ (2006) 'Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies'. Cancer Research, 12 (17):5165-5173 [DOI] [Details]
(2006) 'Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies'
Jilani I, Keating M, Day A, William W, Kantarjian H, O'brien S, Giles FJ, Albitar M (2006) 'Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies'. Clinical And Laboratory Haematology, 28 (5):325-331 [DOI] [Details]
(2007) 'EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation'
Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S (2007) 'EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation'. Blood, 109 (1):315-322 [DOI] [Details]
(2007) 'Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML'
Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M (2007) 'Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML'. Blood, 109 (8):3509-3512 [DOI] [Details]
(2007) 'The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia'
Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H (2007) 'The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia'. British journal of haematology, 136 (4):624-627 [DOI] [Details]
(2007) 'Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors'
Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ (2007) 'Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors'. British journal of haematology, 136 (6):800-805 [DOI] [Details]
(2007) 'Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance'
Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) 'Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance'. Blood, 110 (1):313-322 [DOI] [Details]
(2007) 'Ras as a therapeutic target in hematologic malignancies'
Alvarado Y, Giles FJ (2007) 'Ras as a therapeutic target in hematologic malignancies'. Drugs, 12 (2):271-284 [DOI] [Details]
(2007) 'Treatment of acute lymphoblastic leukaemia : a new era'
Apostolidou E, Swords R, Alvarado Y, Giles FJ (2007) 'Treatment of acute lymphoblastic leukaemia : a new era'. Drugs, 67 (15):2153-2171 [Details]
(2008) 'Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance'
Carew JS, Nawrocki ST, Giles FJ, Cleveland JL (2008) 'Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance'. Biologics : targets & therapy, 2 (2):201-204 [Details]
(2008) 'A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies'
Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ (2008) 'A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies'. Cancer Research, 14 (9):2756-2762 [DOI] [Details]
(2008) 'WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation'
Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z (2008) 'WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation'. Cancer Research, 14 (3):788-796 [DOI] [Details]
(2009) 'The toxicities of modern targeted therapies: learning from the price of progress'
Giles FJ (2009) 'The toxicities of modern targeted therapies: learning from the price of progress'. Targeted oncology, 4 (2):65-66 [DOI] [Details]
(2009) 'Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors'
Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ (2009) 'Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors'. Targeted oncology, 4 (2):99-105 [DOI] [Details]
(2009) 'New directions in the treatment of imatinib failure and/or resistance'
Giles FJ (2009) 'New directions in the treatment of imatinib failure and/or resistance'. Seminars in hematology, 46 (2 Suppl 3):1-33 [Details]
(2009) 'Clinical activity of laromustine (Onriginâ„¢) in hematologic malignancies'
Alvarado Y, Swords R, Kelly KR, Giles FJ (2009) 'Clinical activity of laromustine (Onriginâ„¢) in hematologic malignancies'. Expert Review Of Hematology, 2 (5):481-488 [DOI] [Details]
(2010) 'Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy'
Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP (2010) 'Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy'. Blood, 116 (17):3163-3170 [DOI] [Details]
(2010) 'Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib'
Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H (2010) 'Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib'. Pharmacology & therapeutics, 87 (2):197-203 [DOI] [Details]
(2011) 'The Pim kinases: new targets for drug development'
Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F (2011) 'The Pim kinases: new targets for drug development'. Current Drug Targets, 12 (14):2059-2066 [Details]
(2011) 'Cancer--an increasingly target rich environment'
Giles FJ (2011) 'Cancer--an increasingly target rich environment'. Current Drug Targets, 12 (14):1998-2000 [Details]
(2011) 'Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer'
Wang M, Medeiros BC, Erba HP, DeAngelo DJ, Giles FJ, Swords RT (2011) 'Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer'. Expert Opinion On Therapeutic Targets, 15 (3):253-264 [DOI] [Details]
(2011) 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib'
Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS (2011) 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib'. Journal Of Cellular And Molecular Medicine, 15 (10):2057-2070 [DOI] [Details]
(2011) 'Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model'
Abraham J, Nelon LD, Kubicek CB, Kilcoyne A, Hampton ST, Zarzabal LA, Giles FJ, Michalek JE, Rubin BP, Keller C (2011) 'Preclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model'. Sarcoma, 2011 [DOI] [Details]
(2011) 'Targeting aurora kinases in cancer treatment'
Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, Padmanabhan S, Giles FJ, Carew JS (2011) 'Targeting aurora kinases in cancer treatment'. Current Drug Targets, 12 (14):2067-2078 [Details]
(2011) 'Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors'
Ma W, Giles F, Zhang X, Wang X, Zhang Z, Lee TS, Yeh CH, Albitar M (2011) 'Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors'. International Journal Of Laboratory Hematology, 33 (3):326-331 [DOI] [Details]
(2012) 'EPHA3 as a novel therapeutic target in the hematological malignancies'
Keane N, Freeman C, Swords R, Giles FJ (2012) 'EPHA3 as a novel therapeutic target in the hematological malignancies'. Expert Review Of Hematology, 5 (3):325-340 [DOI] [Details]
(2012) 'Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia'
Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G (2012) 'Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia'. European Journal Of Clinical Investigation, 42 (9):1016-1026 [DOI] [Details]
(2012) 'Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia'
O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ (2012) 'Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia'. British journal of haematology, 158 (5):581-588 [DOI] [Details]
(2012) 'Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism'
Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS (2012) 'Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism'. International Journal Of Cancer, 131 (11):2693-2703 [DOI] [Details]
(2012) 'Targeting PIM kinase activity significantly augments the efficacy of cytarabine'
Kelly KR, Espitia CM, Taverna P, Choy G, Padmanabhan S, Nawrocki ST, Giles FJ, Carew JS (2012) 'Targeting PIM kinase activity significantly augments the efficacy of cytarabine'. British journal of haematology, 156 (1):129-132 [DOI] [Details]
(2012) 'Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening'
Rickles RJ, Tam WF, Giordano TP 3rd, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS (2012) 'Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening'. Molecular Cancer Therapeutics, 11 (7):1432-1442 [DOI] [Details]
(2012) 'An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma'
Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C (2012) 'An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma'. Biochem, 426 (3):363-368 [DOI] [Details]
(1989) 'Molecular analysis of Philadelphia positive essential thrombocythemia'
Martiat P, Ifrah N, Rassool F, Morgan G, Giles F, Gow J, Goldman JM (1989) 'Molecular analysis of Philadelphia positive essential thrombocythemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 3 (8):563-565 [Details]
(1990) 'Chlorambucil lung toxicity'
Giles FJ, Smith MP, Goldstone AH (1990) 'Chlorambucil lung toxicity'. Acta haematologica, 83 (3):156-158 [Details]
(1991) 'Bacterial infections in lymphoma patients treated with recombinant interleukin-2'
Lim SH, Giles FJ, Smith MP, Goldstone AH (1991) 'Bacterial infections in lymphoma patients treated with recombinant interleukin-2'. Acta haematologica, 85 (3):135-138 [Details]
(1991) 'Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias'
Lim SH, Worman C, Jewell A, Tsakona C, Giles FJ, Goldstone A (1991) 'Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias'. Cancer Immunology Immunotherapy, 33 (2):133-137 [Details]
(1994) 'Recombinant interferon-alpha 2 antibodies in chronic lymphocytic leukemia'
McSweeney EN, Giles FJ, Goldstone AH (1994) 'Recombinant interferon-alpha 2 antibodies in chronic lymphocytic leukemia'. Journal of interferon research, 14 (4):191-192 [Details]
(1998) 'Chronic lymphocytic leukemia in (Richter's) transformation'
Giles FJ, O'Brien SM, Keating MJ (1998) 'Chronic lymphocytic leukemia in (Richter's) transformation'. Seminars in oncology, 25 (1):117-125 [Details]
(1999) 'A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission'
Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH (1999) 'A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission'. Cancer, 85 (7):1506-1513 [Details]
(1999) 'Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study'
Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ (1999) 'Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study'. Leuk Lymphoma, 36 (1-2):57-65 [DOI] [Details]
(2000) 'Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia'
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ (2000) 'Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia'. Journal Of Clinical Oncology, 18 (3):547-561 [Details]
(2001) 'Rituximab dose-escalation trial in chronic lymphocytic leukemia'
O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ (2001) 'Rituximab dose-escalation trial in chronic lymphocytic leukemia'. Journal Of Clinical Oncology, 19 (8):2165-2170 [Details]
(2001) 'Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia'
Cortes J, O'Brien S, Loscertales J, Kantarjian H, Giles F, Thomas D, Koller C, Keating M (2001) 'Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia'. Cancer, 92 (8):2016-2022 [Details]
(2001) 'Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia'
O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M (2001) 'Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia'. Journal Of Clinical Oncology, 19 (5):1414-1420 [Details]
(2002) 'Essential thrombocythemia (ET): moving from palliation to cure'
Tsimberidou AM, Giles FJ (2002) 'Essential thrombocythemia (ET): moving from palliation to cure'. Hematology, 7 (6):315-323 [DOI] [Details]
(2002) 'The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia'
Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M (2002) 'The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia'. Blood, 100 (4):1215-1219 [Details]
(2002) 'Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis'
Colburn DE, Welch MA, Giles FJ (2002) 'Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis'. Hematology, 7 (3):187-188 [DOI] [Details]
(2003) 'Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia'
Ibrahim S, Jilani I, O'Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M, Albitar M (2003) 'Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia'. Cancer, 97 (8):1914-1919 [DOI] [Details]
(2003) 'Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia'
Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ (2003) 'Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia'. Cancer, 97 (7):1711-1720 [DOI] [Details]
(2003) 'Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance'
Manshouri T, Do KA, Wang X, Giles FJ, O'Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M (2003) 'Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance'. Blood, 101 (7):2507-2513 [DOI] [Details]
(2003) 'Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia'
Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O'Brien SM (2003) 'Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia'. Cancer Chemother Pharmacol, 52 (3):223-228 [DOI] [Details]
(2003) 'Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia'
Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F, Keating M, Albitar M (2003) 'Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia'. Blood, 102 (10):3514-3520 [DOI] [Details]
(2003) 'Molecular differences between small and large cells in patients with chronic lymphocytic leukemia'
Lee JN, Giles F, Huh YO, Manshouri T, O'Brien S, Kantarjian HM, Keating MJ, Albitar M (2003) 'Molecular differences between small and large cells in patients with chronic lymphocytic leukemia'. European journal of haematology, 71 (4):235-242 [Details]
(2003) 'Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease'
Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O'Brien SM (2003) 'Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease'. Leuk Lymphoma, 44 (10):1719-1725 [DOI] [Details]
(2003) 'Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia'
Colburn DE, Thomas DA, Giles FJ (2003) 'Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia'. Drugs, 21 (1):109-111 [Details]
(2003) 'Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia'
O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ (2003) 'Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia'. Cancer, 98 (12):2657-2663 [DOI] [Details]
(2003) 'Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia'
Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles FJ (2003) 'Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia'. Cancer Chemother Pharmacol, 51 (1):81-86 [DOI] [Details]
(2003) 'Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse'
Leopold LH, Berger MS, Cheng SC, Cortes-Franco JE, Giles FJ, Estey EH (2003) 'Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse'. Hematological Oncology, 1 (4):220-225 [Details]
(2004) 'Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate'
Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H (2004) 'Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate'. Blood, 103 (12):4396-4407 [DOI] [Details]
(2004) 'Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies'
Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M (2004) 'Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies'. Cancer, 101 (5):999-1008 [DOI] [Details]
(2004) 'Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia'
Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ (2004) 'Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia'. Cancer, 101 (12):2788-2801 [DOI] [Details]
(2004) 'The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia'
Ma Y, Mansour A, Bekele BN, Zhou X, Keating MJ, O'Brien S, Giles FJ, Albitar M (2004) 'The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia'. Cancer, 100 (10):2167-2175 [DOI] [Details]
(2004) 'Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia'
Verstovsek S, Giles FJ, O'Brien S, Faderl S, Kantarjian HM, Keating MJ, Albitar M (2004) 'Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia'. Leukemia research, 28 (7):707-711 [DOI] [Details]
(2004) 'Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia'
Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S (2004) 'Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia'. Cancer, 100 (12):2583-2591 [DOI] [Details]
(2005) 'AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells'
Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M (2005) 'AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells'. Cancer, 104 (6):1230-1236 [DOI] [Details]
(2005) 'Monoclonal antibodies in the treatment of leukemia'
O'Brien S, Albitar M, Giles FJ (2005) 'Monoclonal antibodies in the treatment of leukemia'. Molecular Medicine, 5 (7):663-675 [Details]
(2005) 'Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia'
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H (2005) 'Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia'. Cancer Research, 11 (21):7817-7824 [DOI] [Details]
(2005) 'Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia'
Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M (2005) 'Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia'. Journal Of Clinical Oncology, 23 (18):4070-4078 [DOI] [Details]
(2005) 'Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia'
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H (2005) 'Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia'. Journal Of Clinical Oncology, 23 (18):4079-4088 [DOI] [Details]
(2005) 'T-cell prolymphocytic leukemia: a single-institution experience'
Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M (2005) 'T-cell prolymphocytic leukemia: a single-institution experience'. Clinical Lymphoma & Myeloma, 6 (3):234-239 [DOI] [Details]
(2005) 'The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy'
Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Rios MB, Shan J, Cortes J (2005) 'The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy'. Leuk Lymphoma, 46 (7):993-997 [DOI] [Details]
(2005) 'Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate'
Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H (2005) 'Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate'. Cancer Research, 11 (9):3425-3432 [DOI] [Details]
(2005) 'Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy'
Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J (2005) 'Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy'. Cancer, 104 (4):777-780 [DOI] [Details]
(2005) 'Outcome of patients with acute myelogenous leukemia after second salvage therapy'
Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H (2005) 'Outcome of patients with acute myelogenous leukemia after second salvage therapy'. Cancer, 104 (3):547-554 [DOI] [Details]
(2005) 'AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia'
Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M (2005) 'AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia'. Cancer Research, 11 (13):4941-4947 [DOI] [Details]
(2005) 'Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia'
Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M (2005) 'Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia'. Blood, 106 (13):4303-4307 [DOI] [Details]
(2005) 'Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells'
Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P (2005) 'Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 19 (12):2153-2158 [DOI] [Details]
(2005) 'Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia'
Giles FJ, Cortes JE, Kantarjian HM (2005) 'Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia'. Molecular Medicine, 5 (7):615-623 [Details]
(2005) 'Mammalian target of rapamycin as a therapeutic target in leukemia'
Giles FJ, Albitar M (2005) 'Mammalian target of rapamycin as a therapeutic target in leukemia'. Molecular Medicine, 5 (7):653-661 [Details]
(2005) 'Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias'
Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M (2005) 'Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 19 (9):1567-1572 [DOI] [Details]
(2006) 'Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate'
O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J, Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N (2006) 'Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 20 (10):1767-1773 [DOI] [Details]
(2006) 'Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia'
Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H (2006) 'Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia'. Cancer, 106 (1):120-127 [DOI] [Details]
(2006) 'Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy'
Borthakur G, Kantarjian H, Daley G, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Faderl S, Sugrue M, Cortes J (2006) 'Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy'. Cancer, 106 (2):346-352 [DOI] [Details]
(2006) 'Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older'
Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM (2006) 'Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older'. Blood, 108 (1):45-51 [DOI] [Details]
(2006) 'Pregnancy among patients with chronic myeloid leukemia treated with imatinib'
Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J (2006) 'Pregnancy among patients with chronic myeloid leukemia treated with imatinib'. Journal Of Clinical Oncology, 24 (7):1204-1208 [DOI] [Details]
(2006) 'Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA'
Ma W, Kantarjian H, Jilani I, Gorre M, Bhalla K, Ottmann O, Giles F, Albitar M (2006) 'Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 20 (11):1989-1991 [DOI] [Details]
(2006) 'Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome'
Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ (2006) 'Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome'. Leukemia research, 30 (7):813-822 [DOI] [Details]
(2006) 'Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia'
Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H (2006) 'Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia'. Cancer, 106 (7):1569-1580 [DOI] [Details]
(2006) 'Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells'
Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K (2006) 'Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells'. Blood, 108 (2):645-652 [DOI] [Details]
(2006) 'Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure'
Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima M (2006) 'Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure'. Blood, 108 (4):1421-1423 [DOI] [Details]
(2006) 'FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting'
Giles FJ (2006) 'FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting'. Leukemia research, 30 (12):1469-1470 [DOI] [Details]
(2006) 'Clone wars in CML'
Giles FJ (2006) 'Clone wars in CML'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 20 (6):939-940 [DOI] [Details]
(2006) 'Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?'
Verstovsek S, Giles F, Quintás-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H (2006) 'Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?'. Hematological Oncology, 24 (4):181-188 [DOI] [Details]
(2006) 'A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome'
Quintás-Cardama A, Abruzzo LV, Giles FJ, Jorgensen J, Cortes J, Sarriera JE, Kantarjian H, Verstovsek S (2006) 'A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 20 (9):1638-1640 [DOI] [Details]
(2006) 'New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance'
Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J (2006) 'New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance'. Annals Of Internal Medicine, 145 (12):913-923 [Details]
(2006) 'Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia'
Quintas-Cardama A, Kantarjian H, O'Brien S, Jabbour E, Giles F, Ravandi F, Faderl S, Pierce S, Shan J, Verstovsek S, Cortes J (2006) 'Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia'. Cancer, 107 (7):1525-1529 [DOI] [Details]
(2006) 'Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center'
Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G (2006) 'Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center'. Blood, 107 (3):880-884 [DOI] [Details]
(2006) 'Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain'
Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T (2006) 'Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain'. Blood, 107 (1):293-300 [DOI] [Details]
(2006) 'The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)'
Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW (2006) 'The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)'. Leukemia research, 30 (7):801-811 [DOI] [Details]
(2006) 'A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens'
Wierda W, O'brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M (2006) 'A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens'. Cancer, 106 (2):337-345 [DOI] [Details]
(2006) 'Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome'
Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E (2006) 'Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome'. Cancer, 106 (5):1090-1098 [DOI] [Details]
(2006) 'Eradication of minimal residual disease in hairy cell leukemia'
Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM (2006) 'Eradication of minimal residual disease in hairy cell leukemia'. Blood, 107 (12):4658-4662 [DOI] [Details]
(2006) 'Cloretazine for the treatment of acute myeloid leukemia'
Vey N, Giles F (2006) 'Cloretazine for the treatment of acute myeloid leukemia'. Cancer, 6 (3):321-328 [DOI] [Details]
(2006) 'Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia'
Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H (2006) 'Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia'. Cancer, 106 (7):1587-1594 [DOI] [Details]
(2006) 'Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia'
Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O'Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M (2006) 'Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia'. Blood, 108 (3):1001-1006 [DOI] [Details]
(2006) 'A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia'
Giles F, Verstovsek S, Faderl S, Vey N, Karp J, Roboz G, Khan KD, Cooper M, Bilgrami SF, Ferrant A, Daenen S, Karsten V, Cahill A, Albitar M, Kantarjian H, O'Brien S, Feldman E (2006) 'A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia'. Leukemia research, 30 (12):1591-1595 [DOI] [Details]
(2006) 'Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome'
Roboz GJ, Giles FJ, List AF, Cortes JE, Carlin R, Kowalski M, Bilic S, Masson E, Rosamilia M, Schuster MW, Laurent D, Feldman EJ (2006) 'Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 20 (6):952-957 [DOI] [Details]
(2006) 'Novel agents in acute myeloid leukemia'
Aribi A, Ravandi F, Giles F (2006) 'Novel agents in acute myeloid leukemia'. Cancer, 12 (2):77-91 [Details]
(2006) 'Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells'
Verstovsek S, Giles FJ, Quintás-Cardama A, Manshouri T, Huynh L, Manley P, Cortes J, Tefferi A, Kantarjian H (2006) 'Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells'. Leukemia research, 30 (12):1499-1505 [DOI] [Details]
(2006) 'Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia'
Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J (2006) 'Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia'. Blood, 108 (6):1835-1840 [DOI] [Details]
(2006) 'A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse'
Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G (2006) 'A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse'. Leukemia research, 30 (7):777-783 [DOI] [Details]
(2006) 'Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit'
Verstovsek S, Akin C, Manshouri T, Quintás-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H (2006) 'Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit'. Leukemia research, 30 (11):1365-1370 [DOI] [Details]
(2006) 'Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells'
Orsolic N, Golemovic M, Quintás-Cardama A, Scappini B, Manshouri T, Chandra J, Basic I, Giles F, Kantarjian H, Verstovsek S (2006) 'Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells'. Cancer Science, 97 (9):952-960 [DOI] [Details]
(2006) 'Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis'
Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O'Brien S, Giles F, Albitar M (2006) 'Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis'. Cytometry, 70 (4):270-275 [DOI] [Details]
(2007) 'Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance'
Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P (2007) 'Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance'. Blood, 110 (10):3540-3546 [DOI] [Details]
(2007) 'Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure'
Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J (2007) 'Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure'. Blood, 109 (2):497-499 [DOI] [Details]
(2007) 'MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation'
Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) 'MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation'. Blood, 109 (2):500-502 [DOI] [Details]
(2007) 'Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma'
Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) 'Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 21 (2):333-339 [DOI] [Details]
(2007) 'Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia'
Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S (2007) 'Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia'. Journal Of Clinical Oncology, 25 (1):25-31 [DOI] [Details]
(2007) 'Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)'
Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M (2007) 'Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML)'. Leukemia research, 31 (6):791-797 [DOI] [Details]
(2007) 'Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy'
Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O'brien S, Giles FJ (2007) 'Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 21 (3):480-488 [DOI] [Details]
(2007) 'Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia'
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) 'Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia'. Blood, 109 (1):52-57 [DOI] [Details]
(2007) 'New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance'
Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H (2007) 'New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance'. Seminars in hematology, 44 (1 Suppl 1):1-31 [DOI] [Details]
(2007) 'A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma'
Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, Facon T, Fanin R, Caballero D, Ben-Yehuda D, Giles F (2007) 'A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma'. Leuk Lymphoma, 48 (1):39-45 [DOI] [Details]
(2007) 'A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase'
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J (2007) 'A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase'. Leuk Lymphoma, 48 (2):283-289 [DOI] [Details]
(2007) 'Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia'
Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ (2007) 'Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia'. Journal Of Clinical Oncology, 25 (1):10-15 [DOI] [Details]
(2007) 'Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy'
Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J (2007) 'Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy'. Cancer, 109 (2):248-255 [DOI] [Details]
(2007) 'Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia'
Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O'Brien S, Giles F, Albitar M (2007) 'Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia'. Haematologica, 92 (2):170-175 [Details]
(2007) 'Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia'
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M (2007) 'Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia'. Blood, 109 (11):4679-4685 [DOI] [Details]
(2007) 'Important therapeutic targets in chronic myelogenous leukemia'
Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J (2007) 'Important therapeutic targets in chronic myelogenous leukemia'. Cancer Research, 13 (4):1089-1097 [DOI] [Details]
(2007) 'Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure'
Kantarjian H, O'Brien S, Talpaz M, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Rios MB, Shan J, Giles F, Cortes J (2007) 'Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure'. Cancer, 109 (8):1556-1560 [DOI] [Details]
(2007) 'Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia'
Alvarado Y, Apostolidou E, Swords R, Giles FJ (2007) 'Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia'. Drugs, 12 (1):165-179 [DOI] [Details]
(2007) 'A new era for ribonucleoside reductase inhibition'
Giles FJ (2007) 'A new era for ribonucleoside reductase inhibition'. Leukemia research, 31 (9):1163-1164 [DOI] [Details]
(2007) 'Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia'
Swords R, Alvarado Y, Cortes J, Giles FJ (2007) 'Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia'. Current hematologic malignancy reports, 2 (2):83-88 [DOI] [Details]
(2007) 'Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges'
Jabbour E, Cortes J, O'Brien S, Rios MB, Giles F, Kantarjian H (2007) 'Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges'. Clinical Lymphoma & Myeloma, 7 Suppl 2 :1-7 [Details]
(2007) 'Current and emerging treatment options in chronic myeloid leukemia'
Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM (2007) 'Current and emerging treatment options in chronic myeloid leukemia'. Cancer, 109 (11):2171-2181 [DOI] [Details]
(2007) 'The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1'
Pan J, Quintás-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S (2007) 'The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 21 (7):1395-1404 [DOI] [Details]
(2007) 'Nelarabine activity in acute biphenotypic leukemia'
Alvarado Y, Welch MA, Swords R, Bruzzi J, Schlette E, Giles FJ (2007) 'Nelarabine activity in acute biphenotypic leukemia'. Leukemia research, 31 (11):1600-1603 [DOI] [Details]
(2007) 'Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity'
Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M (2007) 'Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity'. Cancer, 110 (2):340-344 [DOI] [Details]
(2007) 'Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML'
Giles FJ (2007) 'Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML'. Leuk Lymphoma, 48 (6):1064-1066 [DOI] [Details]
(2007) 'UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia'
Singer JB, Shou Y, Giles F, Kantarjian HM, Hsu Y, Robeva AS, Rae P, Weitzman A, Meyer JM, Dugan M, Ottmann OG (2007) 'UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 21 (11):2311-2315 [DOI] [Details]
(2007) 'Hairy cell leukemia'
Swords R, Giles F (2007) 'Hairy cell leukemia'. Medical oncology (Northwood, London, England), 24 (1):7-15 [Details]
(2007) 'Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System'
Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H (2007) 'Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System'. Leuk Lymphoma, 48 (6):1150-1160 [DOI] [Details]
(2007) 'Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome'
Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G (2007) 'Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome'. Blood, 110 (7):2302-2308 [DOI] [Details]
(2007) 'Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure'
Cortes J, Quintás-Cardama A, Garcia-Manero G, O'Brien S, Jones D, Faderl S, Ebarb T, Giles F, Thomas D, Kantarjian H (2007) 'Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure'. Cancer, 110 (9):2000-2006 [DOI] [Details]
(2007) 'Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment'
Jabbour E, Cortes J, Giles F, Kantarjian H (2007) 'Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment'. Cancer, 13 (6):357-365 [DOI] [Details]
(2007) 'Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond'
Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H (2007) 'Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond'. Idrugs, 10 (7):468-479 [Details]
(2007) 'Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project'
McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM, Kuzel TM, Trifilio SM, Raisch DW, Kell J, DeAngelo DJ, Giles FJ (2007) 'Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project'. Leukemia research, 31 (5):599-604 [DOI] [Details]
(2007) 'Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors'
Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D (2007) 'Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors'. Blood, 110 (12):4005-4011 [DOI] [Details]
(2008) 'Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia'
Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J (2008) 'Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia'. Seminars in oncology, 35 (1 Suppl 1):1-1 [DOI] [Details]
(2008) 'Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia'
Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M (2008) 'Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia'. Cancer, 112 (6):1306-1312 [DOI] [Details]
(2008) 'Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy'
Swords R, O'Rafferty C, Giles F, Browne P (2008) 'Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 22 (12):2277-2278 [DOI] [Details]
(2008) 'Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells'
Adams DJ, Sandvold ML, Myhren F, Jacobsen TF, Giles F, Rizzieri DA (2008) 'Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells'. Leuk Lymphoma, 49 (4):786-797 [DOI] [Details]
(2008) 'Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors'
Cortes JE, Jabbour E, Breeden M, Giles FJ, Zhao W, Kantarjian HM, Jones D, Thomas D, Yin CC, O'Brien S (2008) 'Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors'. Cancer, 113 (5):985-994 [DOI] [Details]
(2008) 'Current status of therapy for chronic myeloid leukemia: a review of drug development'
Padmanabhan S, Ravella S, Curiel T, Giles F (2008) 'Current status of therapy for chronic myeloid leukemia: a review of drug development'. Future oncology (London, England), 4 (3):359-377 [DOI] [Details]
(2008) 'A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia'
Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ (2008) 'A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia'. Drugs, 26 (4):331-338 [DOI] [Details]
(2008) 'An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation'
Jilani I, Kantarjian H, Faraji H, Gorre M, Cortes J, Ottmann O, Bhalla K, O'Brien S, Giles F, Albitar M (2008) 'An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation'. Leukemia research, 32 (6):936-943 [DOI] [Details]
(2008) 'Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism'
Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P (2008) 'Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 22 (6):1191-1199 [DOI] [Details]
(2008) 'Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia'
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Kwong YL, Baccarani M, Hughes T, Martinelli G, Radich JP, Zheng M, Shou Y, Kantarjian H (2008) 'Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia'. Blood, 111 (4):1834-1839 [DOI] [Details]
(2008) 'Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy'
Jilani I, Kantarjian H, Gorre M, Cortes J, Ottmann O, Bhalla K, Giles FJ, Albitar M (2008) 'Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy'. Leukemia research, 32 (4):643-649 [DOI] [Details]
(2008) 'A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders'
Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J (2008) 'A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders'. Leukemia research, 32 (1):71-77 [DOI] [Details]
(2009) 'Proteomics-based prediction of clinical response in acute myeloid leukemia'
Albitar M, Potts SJ, Giles FJ, O'Brien S, Jilani I, Donahue AC, Estey EH, Kantarjian H (2009) 'Proteomics-based prediction of clinical response in acute myeloid leukemia'. Experimental Hematology, 37 (7):784-790 [DOI] [Details]
(2009) 'Laromustine: the return of alkylators to non-myeloablative therapy of AML'
Giles FJ (2009) 'Laromustine: the return of alkylators to non-myeloablative therapy of AML'. Leukemia research, 33 (8):1022-1023 [DOI] [Details]
(2009) 'Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications'
Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O'Brien S, Keating M, Giles FJ, Albitar M (2009) 'Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications'. Cancer, 5 (1):51-58 [DOI] [Details]
(2009) 'Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow'
Kelly K, Swords R, Kilcoyne A, Sankhala K, Mahalingam D, Padmanabhan S, Giles F (2009) 'Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow'. Leuk Lymphoma, 50 (2):297-299 [DOI] [Details]
(2009) 'Overcoming resistance in chronic myelogenous leukemia'
Cooper S, Giles FJ, Savona MR (2009) 'Overcoming resistance in chronic myelogenous leukemia'. Leuk Lymphoma, 50 (11):1785-1793 [DOI] [Details]
(2009) 'Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia'
Yeh CH, Tseng R, Zhang Z, Cortes J, O'Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M (2009) 'Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia'. Leukemia research, 33 (2):212-217 [DOI] [Details]
(2009) 'Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation'
Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Müller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, Yagasaki F, Pearson JD, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman JM, Zhou W (2009) 'Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation'. Blood, 114 (26):5271-5278 [DOI] [Details]
(2009) 'Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse'
Giles F, Vey N, DeAngelo D, Seiter K, Stock W, Stuart R, Boskovic D, Pigneux A, Tallman M, Brandwein J, Kell J, Robak T, Staib P, Thomas X, Cahill A, Albitar M, O'Brien S (2009) 'Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse'. Blood, 114 (19):4027-4033 [DOI] [Details]
(2009) 'Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia'
Giles FJ, O'Dwyer M, Swords R (2009) 'Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 23 (10):1698-1707 [DOI] [Details]
(2009) 'Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation'
Abrahamsson AE, Geron I, Gotlib J, Dao KH, Barroga CF, Newton IG, Giles FJ, Durocher J, Creusot RS, Karimi M, Jones C, Zehnder JL, Keating A, Negrin RS, Weissman IL, Jamieson CH (2009) 'Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation'. Proc Natl Acad Sci U S A, 106 (10):3925-3929 [DOI] [Details]
(2009) 'Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia'
Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M (2009) 'Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia'. International Journal Of Laboratory Hematology, 31 (1):97-105 [DOI] [Details]
(2009) 'Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib'
Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F (2009) 'Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib'. Drug design, development and therapy, 3 :89-101 [Details]
(2009) 'Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome'
Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O'Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M (2009) 'Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome'. Cancer Research, 15 (11):3820-3826 [DOI] [Details]
(2009) 'High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses'
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, Salvado A, McDougall K, Albitar M, Radich J (2009) 'High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses'. Journal Of Clinical Oncology, 27 (28):4754-4759 [DOI] [Details]
(2010) 'Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents'
Kelly K, Swords R, Mahalingam D, Giles FJ (2010) 'Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents'. Leuk Lymphoma, 51 (8):1399-1413 [DOI] [Details]
(2010) 'Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia'
Schiller GJ, O'Brien SM, Pigneux A, Deangelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ (2010) 'Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia'. Journal Of Clinical Oncology, 28 (5):815-821 [DOI] [Details]
(2010) 'Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study'
Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, Steegmann JL, Valent P, Saglio G (2010) 'Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study'. Expert Review Of Hematology, 3 (6):665-673 [DOI] [Details]
(2010) 'Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias'
Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S (2010) 'Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias'. Blood, 116 (22):4591-4599 [DOI] [Details]
(2010) 'Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3'
Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ (2010) 'Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3'. Journal Of Clinical Oncology, 28 (28):4339-4345 [DOI] [Details]
(2010) 'Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy'
Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM (2010) 'Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 24 (7):1299-1301 [DOI] [Details]
(2010) 'Treating imatinib resistance in the few in CML-A key step towards cure in all'
Giles FJ (2010) 'Treating imatinib resistance in the few in CML-A key step towards cure in all'. Leukemia research, 34 (9):1123-1124 [DOI] [Details]
(2010) 'Circulating CD33 and its clinical value in acute leukemia'
Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey J, Giles F, Albitar M (2010) 'Circulating CD33 and its clinical value in acute leukemia'. Experimental Hematology, 38 (6):462-471 [DOI] [Details]
(2011) 'Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia'
Burke AC, Giles FJ (2011) 'Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia'. Drugs, 20 (12):1707-1715 [DOI] [Details]
(2011) 'A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia'
Abdel-Karim I, Plunkett WK Jr, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM (2011) 'A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia'. Drugs, 29 (2):323-331 [DOI] [Details]
(2011) 'Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results'
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD (2011) 'Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results'. Blood, 117 (4):1141-1145 [DOI] [Details]
(2011) 'A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia'
Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE (2011) 'A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 25 (12):1808-1814 [DOI] [Details]
(2011) 'Current status of agents active against the T315I chronic myeloid leukemia phenotype'
Burke AC, Swords RT, Kelly K, Giles FJ (2011) 'Current status of agents active against the T315I chronic myeloid leukemia phenotype'. Drugs, 16 (1):85-103 [DOI] [Details]
(2012) 'Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia'
Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, DeAngelo DJ, Giles FJ, Marie JP (2012) 'Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia'. Drugs, 30 (3):1121-1131 [DOI] [Details]
(2012) 'Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?'
Freeman CL, Swords R, Giles FJ (2012) 'Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?'. Expert Review Of Hematology, 5 (1):17-26 [DOI] [Details]
(2012) 'Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia'
Swords R, Freeman C, Giles F (2012) 'Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 (10):2176-2185 [DOI] [Details]
(2012) 'Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia'
Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM (2012) 'Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia'. European Journal Of Clinical Pharmacology, [DOI] [Details]
(2012) 'Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies'
Giles FJ, Vey N, Rizzieri D, Ravandi F, Prebet T, Borthakur G, Jacobsen TF, Hagen S, Nilsson B, O'Brien S (2012) 'Phase I and pharmacokinetic study of elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 (7):1686-1689 [DOI] [Details]
(2012) 'MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia'
Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE (2012) 'MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, [DOI] [Details]
(2012) 'Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study'
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM (2012) 'Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, [DOI] [Details]
(2012) 'Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia'
Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S (2012) 'Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia'. Leukemia research, 36 (4):1-3 [DOI] [Details]
(2006) 'Troxacitabine in leukemia'
Swords, R,Apostolidou, E,Giles, F (2006) 'Troxacitabine in leukemia'. Hematology, 11 :321-329 [DOI] [Details]
(2007) 'Troxacitabine in acute leukemia'
Swords, R,Giles, F (2007) 'Troxacitabine in acute leukemia'. Hematology, 12 :219-227 [DOI] [Details]
(2007) 'Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia'
Swords, R,Alvarado, Y,Giles, F (2007) 'Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia'. Clinical Lymphoma & Myeloma, 7 :113-119 [Details]
(2010) 'Cdc7 kinase - a new target for drug development'
Swords R, Mahalingam D, O'Dwyer M, Santocanale C, Kelly K, Carew J, Giles F (2010) 'Cdc7 kinase - a new target for drug development'. European Journal Of Cancer, 46 (1):33-40 [DOI] [Details]
(2010) 'Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'
Swords, RT,Kelly, KR,Smith, PG,Garnsey, JJ,Mahalingam, D,Medina, E,Oberheu, K,Padmanabhan, S,O'Dwyer, M,Nawrocki, ST,Giles, FJ,Carew, JS (2010) 'Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 :3796-3800 [DOI] [Details]
(2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'
Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K,Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS (2010) 'Inhibition of EDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia'. Blood, 115 (18):3796-3800 [DOI] [Details]
(2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'
Cronin CG, Swords R, Truong MT, Viswanathan C, Rohren E, Giles FJ, O'Dwyer M, (2010) 'Bruzzi JF. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010'. Review, 191 (1):W91-W103 [DOI] [Details]
(2011) 'Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma'
Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST (2011) 'Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma'. Br J Cancer, 105 (10):1563-1573 [DOI] [Details]
(2011) 'A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy'
Swords RT, Anguita J, Higgins RA, Yunes AC, Naski M, Padmanabhan S, Kelly KR, Mahalingam D, Philbeck T, Miller L, Puga TA, Giles FJ, Kinney MC, Brenner AJ (2011) 'A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy'. Journal Of Clinical Pathology, 64 (9):809-813 [DOI] [Details]
(2011) 'Elacytarabine - lipid vector technology overcoming drug resistance in acute myeloid leukemia'
Burke, AC,Giles, FJ (2011) 'Elacytarabine - lipid vector technology overcoming drug resistance in acute myeloid leukemia'. Expert Opinion On Investigational Drugs, 20 :1707-1715 [DOI] [Details]
(2011) 'Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib'
Cortes, JE,Hochhaus, A,le Coutre, PD,Rosti, G,Pinilla-Ibarz, J,Jabbour, E,Gillis, K,Woodman, RC,Blakesley, RE,Giles, FJ,Kantarjian, HM,Baccarani, M (2011) 'Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib'. Blood, 117 :5600-5606 [DOI] [Details]
(2012) 'Clinical cardiac safety profile of nilotinib'
Kim, TD,le Coutre, P,Schwarz, M,Grille, P,Levitin, M,Fateh-Moghadam, S,Giles, FJ,Dorken, B,Haverkamp, W,Kohncke, C (2012) 'Clinical cardiac safety profile of nilotinib'. Haematologica-The Hematology Journal, 97 :883-889 [DOI] [Details]
(2012) 'ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma'
Carew JS, Esquivel JA 2nd, Espitia CM, Schultes CM, Mülbaier M, Lewis JD, Janssen B, Giles FJ, Nawrocki ST (2012) 'ELR510444 Inhibits Tumor Growth and Angiogenesis by Abrogating HIF Activity and Disrupting Microtubules in Renal Cell Carcinoma'. Plos One, 7 (1) [DOI] [Details]
(2012) 'Elacytarabine has single-agent activity in patients ?with advanced acute myeloid leukaemia'
O'Brien, S,Rizzieri, DA,Vey, N,Ravandi, F,Krug, UO,Sekeres, MA,Dennis, M,Venditti, A,Berry, DA,Jacobsen, TF,Staudacher, K,Bergeland, T,Giles, FJ (2012) 'Elacytarabine has single-agent activity in patients ?with advanced acute myeloid leukaemia'. British Journal Of Haematology, 158 :581-588 [DOI] [Details]
(2012) 'Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia'
Stone, RM,Fischer, T,Paquette, R,Schiller, G,Schiffer, CA,Ehninger, G,Cortes, J,Kantarjian, HM,DeAngelo, DJ,Huntsman-Labed, A,Dutreix, C,del Corral, A,Giles, F (2012) 'Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 :2061-2068 [DOI] [Details]
(2012) 'Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia'
Yin, OQP,Giles, FJ,Baccarani, M,le Coutre, P,Chiparus, O,Gallagher, N,Saglio, G,Hughes, TP,Hochhaus, A,Kantarjian, HM,Larson, RA (2012) 'Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia'. Cancer Chemotherapy And Pharmacology, 70 :345-350 [DOI] [Details]
(2012) 'Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results'
le Coutre, PD,Giles, FJ,Hochhaus, A,Apperley, JF,Ossenkoppele, GJ,Blakesley, R,Shou, Y,Gallagher, NJ,Baccarani, M,Cortes, J,Kantarjian, HM (2012) 'Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 :1189-1194 [DOI] [Details]
(2012) 'Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase'
Giles, FJ,Kantarjian, HM,le Coutre, PD,Baccarani, M,Mahon, FX,Blakesley, RE,Gallagher, NJ,Gillis, K,Goldberg, SL,Larson, RA,Hochhaus, A,Ottmann, OG (2012) 'Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase'. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 26 :959-962 [DOI] [Details]
(2010) 'Heat Shock Protein 90 regulates the expression of Wilm’s tumor 1 protein in myeloid leukemias'
Bansal, H., Bansal, S., Rao, M., Ying, W., Sang, J., Kelly, K., Swords, R.P., Foley, K.P., Barsoum, J., Repasky, E., Giles, F.J., Lee, K.P., Padmanabhan, S.. (2010) 'Heat Shock Protein 90 regulates the expression of Wilm’s tumor 1 protein in myeloid leukemias'. Blood, 116 :4591-4599 [Details]
(2010) 'MicroCT-based virtual histology evaluation of preclinical medulloblastoma'
Prajapati, S.I., Kilcoyne, A., Samano, A.K., Green, D.P., McCarthy, S.D., Blackman, B.A., Brady, M.M., Zarzabal, L.A., Tatiparthy, A.K., Sledz, T.J., Duong, T., Ohshima-Hosoyama, S., Giles, F.J., Michalek, J.E., Rubin, B.P., Keller, C. (2010) 'MicroCT-based virtual histology evaluation of preclinical medulloblastoma'. Molecular Imaging Biology, [Details]
(2010) 'Lucanthone: A novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis'
Carew, J.S., Esquivel, J.A., Mahalingam, M., Olaya, C.M., Swords, R., Kelly, K., Giles, F.J.,  Nawrocki, S.T. (2010) 'Lucanthone: A novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis'. Journal of Biological Chemistry, [Details]
(2010) 'A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3'
Fisher. T., Stone, R.M., DeAngelo, D., Galinsky, I., Estey, E., Cohen, P., Fox, E., Ehninger, G., Feldman, E.J.,  Schiller, G.J., Klimek, V.M., Nimer, S.D., Gilliland, D.G., Wong, Y.F., Massimini, G., Giles, F.J. (2010) 'A Phase IIB trial of the putative FLT3 and mutlitargeted kinase inhibitor PKC412 (N-benzoylstaurosporine; Midostaurin) in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome with either wild-type or mutated FLT3'. Journal of Clinical Oncology, 28 :4339-4345 [Details]
(2010) 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib'
Kelly, K., Swords, R., Mahalingam, D., Nawrocki, S., Padmanabhan, S., Giles, F., Carew, S (2010) 'The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib'. Journal of Cellular and Molecular Medicine, [Details]
(2010) 'Phase II study of romiplostim in patients with low- or Intermediate-risk myelodysplastic syndrome receiving azacitidine therapy'
Kantarjian, H.M., Giles, F.J., Greenberg, P.L., Paquette, R.L., Wang, E.S., Gabrilove, J.L., Garcia-Manero, G., Hu, K., Franklin, J.L., Berger, D.P (2010) 'Phase II study of romiplostim in patients with low- or Intermediate-risk myelodysplastic syndrome receiving azacitidine therapy'. Blood, 116 :3163-3170 [Details]
(2010) 'Nilotinib, a potent and selective BCR-ABL inhibitor, is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study'
Kantarjian, H.M., Giles, F.J., Bhalla, K.P., Pinilla, J., Larson, R.A., Gattermann, N., Ottmann, O., Hochhaus, A., Radich, J.P., Saglio, G., Hughes, T.P., Martinelli, G., Kim, D.W., Shou, Y., Gallagher, N.J., Blakesley, R., Baccarani, M., Cortes, J., le Coutre, P.D. (2010) 'Nilotinib, a potent and selective BCR-ABL inhibitor, is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study'. Blood, [Details]
(2011) 'Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia'
Lapusan, S., Vidriales, M.B., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., Dumontet, C.,    Morariu-Zamfir, R., Lambert, J.M., Ozoux, M.L., Poncelet, P., San Miguel, J.F ., Legrand, O., De Angelo, D., Giles, F.J. , Marie, J.P (2011) 'Dose-escalation phase I studies of AVE9633, an anti CD33 antibody- maytansinoid conjugate, administered as a single agent by intravenous infusion to adult patients with relapsed or refractory CD33-positive acute myeloid leukemia'. Investigational New Drugs, [Details]
(2011) 'Ubiquitin-Proteasome signature for detection of hepatocellular carcinoma'
Qu, K.Z., Zhang, K., Ma, W., Li, H., Wang, X., Zhang, X., Giles, F., Lai, M., Afdhal, N.H., Albitar, M. (2011) 'Ubiquitin-Proteasome signature for detection of hepatocellular carcinoma'. Journal Gastroenterology and Hepatology, 26 :751-758 [Details]

Book Chapters

  Year Publication
(1993) 'Multiple Myeloma'
Giles FJ, Durie BGM (1993) 'Multiple Myeloma' In: Therapies and Strategies in Oncology. Heidelberg: Springer Verlag. [Details]
(1994) 'Hodgkin's Disease and the Non-Hodgkin's Lymphomas: Diagnosis, Staging and Therapy'
Giles FJ, HH Timmis, Jr. (1994) 'Hodgkin's Disease and the Non-Hodgkin's Lymphomas: Diagnosis, Staging and Therapy' In: The Neck: Diagnosis and Surgery. St. Louis: Mosby-Year Book Inc. [Details]
(1994) 'Myelomatosis'
Giles FJ, Durie BGM (1994) 'Myelomatosis' In: Postgraduate Hematology IVth Ed. London: Butterworth-Heinmann. [Details]
(1995) 'Multiple Myeloma (Plasmozytom)'
Giles FJ (1995) 'Multiple Myeloma (Plasmozytom)' In: Therapies and Strategies in Oncology IInd Ed. Heidelberg: Springer Verlag. [Details]
(1995) 'Multiple myeloma and other differentiated B-cell disorders'
Giles FJ (1995) 'Multiple myeloma and other differentiated B-cell disorders' In: Current Review of Hematology. Philadelphia: Churchill Livingstone. [Details]
(1995) 'Secondary myelodysplastic syndromes and leukemias'
Giles FJ (1995) 'Secondary myelodysplastic syndromes and leukemias' In: Current Review of Hematology. Philadelphia: Churchill Livingstone. [Details]
(1995) 'Multiple myeloma and Waldenstroms Macroglobulinemia'
Giles FJ (1995) 'Multiple myeloma and Waldenstroms Macroglobulinemia' In: Current Therapy in Hematology Oncology Vth Ed. Philadelphia: Mosby-Year Book. [Details]
(1995) 'Cytogenetics and molecular biology of acute myeloid leukemias'
Giles FJ, Koeffler HP (1995) 'Cytogenetics and molecular biology of acute myeloid leukemias' In: Cancer Treatment IVth Edition. Philadelphia: W.B. Saunders. [Details]
(1995) 'Chronic myelogenous leukemia'
Giles FJ, Koeffler HP (1995) 'Chronic myelogenous leukemia' In: Cancer Treatment IVth Edition. Philadelphia: W.B. Saunders. [Details]
(1996) 'Treatment of refractory multiple myeloma with cytotoxic therapy and Radiation therapy'
Giles FJ (1996) 'Treatment of refractory multiple myeloma with cytotoxic therapy and Radiation therapy' In: Multiple Myeloma. New York: Edward Arnold. [Details]
(1996) 'Malignant splenic lesions'
Giles FJ, Lim SW (1996) 'Malignant splenic lesions' In: Surgical Diseases of the Spleen. New York: Springer-Verlag. [Details]
(1996) 'Myeloma and other paraproteinemias'
Durie BGM, Giles FJ (1996) 'Myeloma and other paraproteinemias' In: Oxford Textbook Of Medicine IIIrd Ed. Oxford: Oxford University Press. [Details]
(1996) 'Multiple myeloma and Waldenstroms Macroglobulinemia'
Giles FJ (1996) 'Multiple myeloma and Waldenstroms Macroglobulinemia' In: Current Therapy in Internal Medicine IVth Ed. Philadelphia: Mosby-Year Book. [Details]
(1997) 'Multiple myeloma and Waldenstroms Macroglobulinemia'
Giles FJ (1997) 'Multiple myeloma and Waldenstroms Macroglobulinemia' In: Current Therapy in Adult Medicine. Philadelphia: Mosby-Year Book. [Details]
(1997) 'Treatment of multiple myeloma'
Giles FJ (1997) 'Treatment of multiple myeloma' In: Medical Management of Hematologic Malignant Disease. New York: Marcel Dekker. [Details]
(1997) 'Multiple Myeloma (Plasmozytom)'
Giles FJ (1997) 'Multiple Myeloma (Plasmozytom)' In: Therapies and Strategies in Oncology IIIrd Ed. Heidelberg: Springer Verlag. [Details]
(1998) 'Myelomatosis ( in multiple myeloma)'
Giles FJ, Durie BGM (1998) 'Myelomatosis ( in multiple myeloma)' In: Postgraduate Haematology IVth Ed. London: Butterworth-Heinmann. [Details]
(1999) 'Therapy of Chronic Myelogenous Leukemia'
Giles, FJ, HM Kantarjian (1999) 'Therapy of Chronic Myelogenous Leukemia' In: Oncologic Therapies. Heidelberg: Springer Verlag. [Details]
(2000) 'Multiple Myeloma (Plasmozytom)'
Giles FJ (2000) 'Multiple Myeloma (Plasmozytom)' In: Therapies and Strategies in Oncology IVth Ed. Heidelberg: Springer Verlag. [Details]
(2000) 'Therapy of the acute myeloid leukemias'
Giles FJ, Keating M, Andreeff M (2000) 'Therapy of the acute myeloid leukemias' In: Cancer Treatment Vth Edition. Philadelphia: W.B. Saunders. [Details]
(2003) 'Treatment of invasive Aspergillus infections in BMT patients'
Mattiuzzi G, Alvarez RH, Giles F (2003) 'Treatment of invasive Aspergillus infections in BMT patients' In: Antibiotics for Clinicians, Supplement 1: Fungal Infections in Hospitalized Patients. N/A: AFC Volume 7. [Details]
(2007) 'Approaching the Treatment of AML from a biological perspective: An overview'
Ravandi F, Giles F (2007) 'Approaching the Treatment of AML from a biological perspective: An overview' In: Acute Myelogenous Leukemia. New Jersey: Humana Press. [Details]
(2007) 'Antiangiogenic Therapy for Hematologic Malignancies'
Yee K, Giles FJ (2007) 'Antiangiogenic Therapy for Hematologic Malignancies' In: Antiangiogenic Cancer Therapy. N/A: Catalog 2799. [Details]

Conference Publications

  Year Publication
(2012) Royal Academy of Medicine in Ireland Annual Meeting
Burke, AJ; O'Connell, E; Miranda, KM; Giles, FJ; Sullivan, F; Glynn, SA (2012) Nitric Oxide and its effects on cellular proliferation and phenotype in prostate cancer Royal Academy of Medicine in Ireland Annual Meeting NUI Galway, Ireland, [Details]

Abstract

  Year Publication
(2009) MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Swords, RT,Kelly, KR,Smith, PG,Gansey, JJ,Mahalingam, D,Padmanabhan, S,O'Dwyer, MC,Nawrocki, ST,Giles, FJ,Carew, JS (2009) MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia. Abstract [Details]
(2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study.
O'Dwyer, MC,Kent, E,Parker, M,Swords, RT,Giles, F,le Coutre, P,Padmanabhan, S,Moulton, B,McMullin, MF,Langabeer, S,Egan, K,Conneally, E (2009) Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study. Abstract [Details]
(2010) NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY.
O'Dwyer, E,Swords, R,Giles, F,LeCoutre, P,McMullin, M,Langabeer, S,Padmanabhan, S,Kent, E,Parker, M,Moulton, B,Egan, K,Conneally, E (2010) NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY. Abstract [Details]

Letter

  Year Publication
(2007) Nelarabine activity in acute biphenotypic leukemia.
Alvarado, Y,Welch, MA,Swords, R,Bruzzi, J,Schlette, E,Giles, FJ (2007) Nelarabine activity in acute biphenotypic leukemia. Letter [DOI] [Details]
(2012) Elacytarabine, a novel 5 '-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.
Giles, F,Rizzieri, D,Ravandi, F,Swords, R,Jacobsen, TF,O'Brien, S (2012) Elacytarabine, a novel 5 '-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Letter [DOI] [Details]
(2012) Phase I and pharmacokinetic study of elacytarabine, a novel 5 '-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies.
Giles, FJ,Vey, N,Rizzieri, D,Ravandi, F,Prebet, T,Borthakur, G,Jacobsen, TF,Hagen, S,Nilsson, B,O'Brien, S (2012) Phase I and pharmacokinetic study of elacytarabine, a novel 5 '-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Letter [DOI] [Details]

Meeting

  Year Publication
(2009) OVERCOMING DRUG RESISTANCE WITH SGI-1776: A NOVEL PIM KINASE INHIBITOR WITH POTENT PRECLINICAL ACTIVITY IN ACUTE MYELOID LEUKEMIA.
Swords, T,Kelly, K,Mahalingam, D,O'Dwyer, M,Nawrocki, S,Giles, F,Carew, J (2009) OVERCOMING DRUG RESISTANCE WITH SGI-1776: A NOVEL PIM KINASE INHIBITOR WITH POTENT PRECLINICAL ACTIVITY IN ACUTE MYELOID LEUKEMIA. Meeting [Details]
(2009) ACTIVITY OF MLN4924, A NOVEL FIRST IN CLASS SMALL MOLECULE INHIBITOR OF THE NEDD8 ACTIVATING ENZYME, IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA.
Swords, T,Kelly, K,Smith, P,Mahalingam, D,O'Dwyer, M,Nawrocki, S,Giles, F,Carew, J (2009) ACTIVITY OF MLN4924, A NOVEL FIRST IN CLASS SMALL MOLECULE INHIBITOR OF THE NEDD8 ACTIVATING ENZYME, IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA. Meeting [Details]
(2010) Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR.
Conneally, E,Swords, RT,Giles, FJ,McMullin, MF,le Coutre, P,Langabeer, S,Wieczorkowska, M,McDowell, C,Moulton, B,Egan, K,O'Dwyer, M (2010) Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR. Meeting [Details]
(2010) THE FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), MLN4924, INDUCES STABLE DISEASE REGRESSION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML).
Carew, J,Swords, R,Kelly, K,Smith, P,Garnsey, J,Mahalingam, D,Medina, E,O'Dwyer, M,Oberheu, K,Nawrocki, S,Giles, F (2010) THE FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF NEDD8-ACTIVATING ENZYME (NAE), MLN4924, INDUCES STABLE DISEASE REGRESSION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA (AML). Meeting [Details]
(2011) Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML).
O'Dwyer, ME,Swords, R,Giles, F,McMullin, MF,le Coutre, PD,Nagler, A,Langabeer, S,Wieczorkowska, M,McDowell, C,Egan, K,Moulton, B,Conneally, E (2011) Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML). Meeting [Details]
(2011) Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study.
le Coutre, PD,Giles, FJ,Pinilla-Ibarz, J,Larson, RA,Gattermann, N,Ottmann, OG,Hochhaus, A,Radich, JP,Saglio, G,Hughes, TP,Martinelli, G,Kim, DW,Branford, S,Muller, MC,Shou, YP,Novick, S,Fan, XL,Cortes, JE,Baccarani, M,Kantarjian, HM (2011) Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study. Meeting [Details]
(2011) A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission.
Giles, FJ,Rosti, G,Ossenkoppele, G,Tulliez, M,Stentoft, J,Giagounidis, A,Nobile, F,le Coutre, PD,Gattermann, N,Griskevicius, L,Cross, NCP,Hill, S,Schuld, P,Pellegrino, A,Magazzu, D,Hochhaus, A (2011) A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission. Meeting [Details]
(2011) Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
Giles, FJ,Mauro, MJ,Hong, F,Ortmann, CE,Woodman, RC,LeCoutre, PD,Saglio, G (2011) Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Meeting [Details]

Reviews

  Year Publication
(2012) Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Swords, R,Freeman, C,Giles, F (2012) Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Reviews [DOI] [Details]
(2007) Recent advances in the diagnosis and therapy of Richter's syndrome.
Swords, R,Bruzzi, J,Giles, F (2007) Recent advances in the diagnosis and therapy of Richter's syndrome. Reviews [Details]
(2007) Hairy cell leukemia.
Swords, R,Giles, F (2007) Hairy cell leukemia. Reviews [Details]
(2007) Treatment of acute lymphoblastic leukaemia - A new era.
Apostolidou, E,Swords, R,Alvarado, Y,Giles, FJ (2007) Treatment of acute lymphoblastic leukaemia - A new era. Reviews [Details]
(2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Giles, FJ,O'Dwyer, M,Swords, R (2009) Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Reviews [DOI] [Details]
(2010) Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
Giles, FJ,Rosti, G,Beris, P,Clark, RE,le Coutre, P,Mahon, FX,Steegmann, JL,Valent, P,Saglio, G (2010) Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. Reviews [DOI] [Details]
(2010) Clinical Utility of PET/CT in Lymphoma.
Cronin, CG,Swords, R,Truong, MT,Viswanathan, C,Rohren, E,Giles, FJ,O'Dwyer, M,Bruzzi, JF (2010) Clinical Utility of PET/CT in Lymphoma. Reviews [DOI] [Details]
(2010) Cdc7 kinase - A new target for drug development.
Swords, R,Mahalingam, D,O'Dwyer, M,Santocanale, C,Kelly, K,Carew, J,Giles, F (2010) Cdc7 kinase - A new target for drug development. Reviews [DOI] [Details]
(2011) Targeting Trail Towards the Clinic.
Mahalingam, D,Oldenhuis, CNAM,Szegezdi, E,Giles, FJ,de Vries, EGE,de Jong, S,Nawrocki, ST (2011) Targeting Trail Towards the Clinic. Reviews [Details]
(2011) Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer.
Wang, M,Medeiros, BC,Erba, HP,DeAngelo, DJ,Giles, FJ,Swords, RT (2011) Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Reviews [DOI] [Details]
(2011) Current status of agents active against the T315I chronic myeloid leukemia phenotype.
Burke, AC,Swords, RT,Kelly, K,Giles, FJ (2011) Current status of agents active against the T315I chronic myeloid leukemia phenotype. Reviews [DOI] [Details]
(2012) Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Giles, F,Mahon, FX,Gjertsen, B,Swords, R,Labar, B,Turkina, A,Rosti, G (2012) Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. Reviews [DOI] [Details]
(2012) EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane, N,Freeman, C,Swords, R,Giles, FJ (2012) EPHA3 as a novel therapeutic target in the hematological malignancies. Reviews [DOI] [Details]
(2012) Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?.
Freeman, CL,Swords, R,Giles, FJ (2012) Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. Reviews [DOI] [Details]
(2012) The PIM kinases in hematological cancers.
Alvarado, Y,Giles, FJ,Swords, RT (2012) The PIM kinases in hematological cancers. Reviews [DOI] [Details]